20.500.12556/DiRROS-18796 Febrile neutropenia in chemotherapy treated small-cell lung cancer patients Febrilna nevtropenija pri kemoterapevtskem zdravljenju bolnikov z drobnoceličnim pljučnim rakom Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrileneutropenia. Primary prophylaxis with granulocyte colonystimulating factors (G-CSFs) is not routinely recommended by the treatment guidelines. However, in clinical practice febrile neutropenia is often observed with standard etoposide/platinum regimen. The aim of this analysis was to evaluate the frequency of neutropenia and febrile neutropenia in advanced SCLC patients in the first cycle of standard chemotherapy. Furthermore, we explored the association between severe neutropenia and etoposide peak plasma levels inthe same patients. The case series based analysis of 17 patients with advanced SCLC treated with standard platinum/etoposide chemotherapy, already included in the pharmacokinetics study with etoposide, was performed. Grade 3/4 neutropenia and febrile neutropenia, observed after the first cycle are reported. The neutrophil counts were determined on day one of the second cycle unless symptoms potentially related to neutropenia occurred. Adverse events were classified according to Common Toxicity Criteria 4.0. Additionally, association between severe neutropenia and etoposide peak plasma concentrations, which were measured in the scope of pharmacokinetic study, was explored. Two out of 17 patients received primary GCS-F prophylaxis. In 15 patient who did not receive primary prophylaxis the rates of both grade 3/4 neutropenia and febrile neutropenia were high (8/15 (53.3%) and 2/15 (13.3%), respectively), already in the first cycle of chemotherapy. One patient died due to febrile neutropenia related pneumonia. Neutropenic events are assumed to be related to increased etoposide plasma concentrations after a standard etoposide and cisplatin dose. While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia. Our study indicates that there is a need to reduce the risk of neutropenic events in chemotherapy treated advanced SCLC, starting in the first cycle. Mandatory use of primary G-CSF prophylaxis might be considered. Alternatively, use of improved risk models for identification of patients with increased risk for neutropenia and individualization of primary prophylaxis based on not only clinical characteristics but also on etoposide plasma concentration measurement, could be a new, promising options that deserves further evaluation. small cell lung cancer platinum-etoposide chemotherapy etoposide febrile neutropenia plasma drug concentration true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-04-22 15:08:17 2024-04-22 15:08:18 2024-04-24 03:39:26 0000-00-00 00:00:00 2015 0 0 Soavtorji: Iztok Grabnar, Tomaz Vovk, Ales Mrhar, Viljem Kovac, Tanja Cufer; str. 173-180, VI no. 2 Vol. 49 jun. 2015 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2015-06-01 616.254-006 1318-2099 10.2478/raon-2014-0050 3778929 http://ojs.szd.si/index.php/ro/article/view/2223 El. vir na naslovu: http://ojs.szd.si/index.php/ro/article/view/2223 ni več dostopen (12. 10. 2018) 1 635a26c3-00a9-11ef-ab10-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25712 RAZ_Rezonja_Renata_2015.pdf RAZ_Rezonja_Renata_2015.pdf 1 0067C471EBF4C9C2D6023C9CAB4BE721 4c70e59df0de1e866c0723df9b08ef0b9ead365afa8da690258895ca1c88a545 8f3ee631-00a9-11ef-ab10-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25713 Onkološki inštitut Ljubljana 0 0 0